METABOLIC EFFICIENCY WITH RANOLAZINE FOR LESS ISCHEMIA IN NON-ST ELEVATION ACUTE CORONARY SYNDROMES A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, MULTINATIONAL, CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF RANOLAZINE VERSUS PLACEBO IN PATIENTS WITH NON-ST SEGMENT ELEVATION ACUTE CORONARY SYNDROMES - MERLIN-TIMI 36

CV THERAPEUTICS INC0 个研究点目标入组 6,500 人开始时间: 2004年10月12日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•All inclusion criteria must be met:-
•1) Aged 18 years or older, and
•2) Hospitalisation with non-ST elevation acute coronary syndrome defined as chest discomfort or anginal equivalent occurring at rest, lasting for 10 minutes or more and consistent with myocardial ischemia, and
•3) At least one episode of ischemic symptoms (5 minutes or longer) at rest within 48 hours of enrollment (may include index episode), and
•4) At least one of the indicators of moderate-high risk as detailed in the protocol, and
•5) Willing and able to provide written informed consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Any of the criteria will result in exclusion:-
•1) Persistent (> 20 mins) acute ST-segment elevation of 0.1 mV or greater, in two or more contiguous leads
•2) Successful revascularisation of the culprit stenosis during the qualifying hospitalisation prior to randomisation
•3) Acute pulmonary edema requiring endotracheal intubation, sustained blood pressure < 90 mm Hg or evidence of cardiogenic shock
•4) Left bundle branch block, electronic pacemaker, or LVH with severe repolarizartion abnormality that would interfere with interpretation of the Holter
•5) Other exclusion criteria in the Protocol

发起方